Title: Halozyme Therapeutics Inc (HALO) 10K Annual Reports & 10Q SEC Filings
URL: https://last10k.com/sec-filings/halo

HOME


LOGIN


PREMIUM


FREE TRIAL


SEC FILINGS


STOCK SCREENERS


EARNINGS


TRENDING


STOCKTWITS


INSIDER TRADING


SENTIMENT ANALYSIS


MANAGER PORTFOLIOS


LATE CORPORATE NEWS






				 



Halozyme Therapeutics, Inc. (HALO) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023


Home
SEC Filings
Halozyme Therapeutics Inc (HALO)
10-K Annual Report Tue Feb 20 2024






SEC Filings



 
HALO Valuations





Intrinsic Value





Financial Stability





Financial Ratios





Insider Trades





Manager Portfolios





Notifications





 
HALO Annual Reports
				  





10-K Annual Report February 2024


PDF

PDF


Select PDF Feature:
Include Exhibits
Highlight YoY Changes
Highlight Sentiment

10-K Only


Word
Excel
CSV


Table of Contents
Summary of Risk Factors
Business
Risk Factors
Unresolved Staff Comments
Cybersecurity
Properties
Legal Proceedings
Mine Safety Disclosures
Market For Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Managements Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits, Financial Statement Schedules
Form 10K Summary
SIGNATURES








									10-K Annual Report February 2023																






									10-K Annual Report February 2022																






									10-K Annual Report February 2021																






									10-K Annual Report February 2020																






									10-K Annual Report February 2019																






									10-K Annual Report February 2018																






									10-K Annual Report February 2017																






									10-K Annual Report February 2016																






HALO Quarterly Reports
				  





									10-Q Quarterly Report August 2024																






									10-Q Quarterly Report May 2024																






									10-Q Quarterly Report November 2023																






									10-Q Quarterly Report August 2023																






									10-Q Quarterly Report May 2023																






									10-Q Quarterly Report November 2022																






									10-Q Quarterly Report August 2022																






									10-Q Quarterly Report May 2022																






									10-Q Quarterly Report November 2021																






									10-Q Quarterly Report August 2021																






HALO Corporate News
				  





									Earnings ReleaseFinancial Exhibit																	August 2024







									Earnings ReleaseFinancial Exhibit																	May 2024







									Financial ExhibitVote of Security Holders																	April 2024







									Earnings ReleaseFinancial Exhibit																	February 2024







									Earnings Release																	January 2024







									Earnings ReleaseFinancial Exhibit																	November 2023







									Other Events																	September 2023







									Earnings ReleaseFinancial Exhibit																	August 2023







									Earnings ReleaseFinancial Exhibit																	May 2023







									Vote of Security Holders																	May 2023













Last10K.com | 10-K Annual Report Tue Feb 20 2024






Halozyme Therapeutics Inc


													CIK: 1159036
																										Ticker: HALO




Earnings Press Release
 10-K Annual Report
 10-K YoY Changes
 Annual Proxy




Halozyme Therapeutics Inc

HISTORY
TOOLS


CIK: 1159036
Ticker: HALO




HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTSReiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of      26- 37% and Non-GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41%Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.821Full Year 2023 Revenue Increased 26% YOY to $829 million; GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.771Announcing New $750 million Share Repurchase ProgramSAN DIEGO, February 20, 2024 -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2023 and provided an update on its recent corporate activities and outlook.“We are pleased to reiterate our 2024 financial guidance, which represents continued robust growth of total revenue, royalty revenue, adjusted EBITDA and non-GAAP diluted EPS, and builds upon our strong 2023 performance and results. Multiple, positive, value-creating events including the first approvals of VYVGART Hytrulo and Tecentriq SC and positive phase 3 data readouts with ENHANZE for VYVGART Hytrulo in CIDP, ocrelizumab SC and nivolumab SC all achieved in 2023, add new opportunities for continued revenue growth,” said Dr. Helen Torley, president and chief executive officer of Halozyme. “Today’s announcement of a new $750 million share repurchase program demonstrates our confidence in sustained and durable growth.”Fourth Quarter and Recent Corporate Highlights:•Reiterating 2024 financial guidance announced January 17th including total revenue of $915 million to $985 million, representing year-over-year growth of 10% to 19%, adjusted EBITDA of $535 million to $585 million, representing year-over-year growth of 26% to 37% and non-GAAP diluted earnings per share of $3.55 to $3.90, representing year-over-year growth of 28% to 41%.•In February 2024, the Company announced its third share repurchase program to repurchase up to $750 million of its outstanding common stock.•In November 2023, Halozyme entered into an Accelerated Share Repurchase agreement to accelerate the remaining $250.0 million in share repurchases under the $750 million approved program from December 2021. The following information was filed by Halozyme Therapeutics Inc (HALO) on Tuesday, February 20, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release. 

Please wait while we load the requested 10-K report or click the link below:https://last10k.com/sec-filings/report/1159036/000115903624000008/halo-20231231.htm


View differences made from one year to another to evaluate Halozyme Therapeutics Inc's financial trajectory





Sample 10-K Year-over-Year (YoY) Comparison



Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Halozyme Therapeutics Inc.

Continue







Assess how Halozyme Therapeutics Inc's management team is paid from their Annual Proxy





Screenshot example of actual Proxy Statement




Halozyme Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors


Continue














SEC Filing Tools




 Sentiment
 Sections
 Exhibits
 Stats


 



 Rating					
Learn More










Filter Sentiment:



All






Positive




Negative





Filter Category:




All





Financial







Revenue






Legal






M & A






Mgmt Change






Other






Filter Subcategory:




All






Shares






Product






Income






Expense






Geography






Other







 Inside Halozyme Therapeutics Inc's 10-K Annual Report:


 Financial - Shares   Highlight
However, if actual results are not consistent with our estimates or assumptions, we may be exposed to changes in share-based compensation expense that could be material.



 Other - Other   Highlight
Holders of the notes could convert their notes at any time prior to the close of the business day prior to the redemption date.

 Financial - Shares   Highlight
In December 2021, our Board of Directors authorized a share repurchase program to repurchase up to $750.0 million of our outstanding common stock over a three-year period.

 Financial - Shares   Highlight
In November 2023, we accelerated the initiation of our planned 2024 share repurchases and entered into an ASR agreement with Bank of America to accelerate the remaining $250.0 million of share repurchases under the $750.0 million approved capital return program.

 Other - Other   Highlight
In February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0 million of our outstanding common stock.

 Other - Other
•In February 2024, we announced...Read more

 Other - Other
Concurrently with the entry into...Read more

 Other - Other
•In January 2024, Roche received...Read more

 Revenue - Product
The increase in product sales...Read more

 Financial - Income
The increase in investment and...Read more

 Other - Other
We have development programs including...Read more

 Other - Other
Halozyme Therapeutics, Inc. is a...Read more

 Other - Other
We also develop, manufacture and...Read more

 Other - Other
•In January 2024, Takeda received...Read more

 Other - Other
•In August 2023, ViiV initiated...Read more

 Financial - Expense
The increase in cost of...Read more

 Other - Other
We base our estimates on...Read more

 Financial - Shares
In connection with the 2022...Read more

 Revenue - Product
•In August 2023, we announced...Read more

 Financial - Shares
In connection with the 2021...Read more

 Financial - Expense
•the costs of investments in...Read more

 Other - Other
In July 2023, argenx reported...Read more

 Revenue - Product
•In August 2023, Roche announced...Read more

 Other - Other
The Amendment, among other things,...Read more

 Financial - Expense
•the costs to expand the...Read more

 Revenue - Product
We expect sales of our...Read more

 Financial - Shares
In connection with the conversion,...Read more

 Other - Other
•In January 2023, we elected...Read more

 Other - Other
Our commercial portfolio of proprietary...Read more

 Other - Other
Lastly, certain proprietary drugs co-formulated...Read more

 Revenue - Product
Differences in the allocation of...Read more

 Other - Other
Purchase obligations represent an estimate...Read more

 Revenue - Product
We are entitled to receive...Read more

 Other - Other
Under these agreements, we are...Read more

 Legal - Other
Contractual obligations for purchases of...Read more

 Revenue - Product
•In June 2023, argenx received...Read more

 Other - Other
•In August 2023, ViiV achieved...Read more

 Revenue - Geography
The European approval of VYVGART...Read more

 Other - Other
In the development of proprietary...Read more

 Revenue - Product
Therefore, we recognize revenue based...Read more

 Financial - Shares
•During 2023, we repurchased 4.2...Read more

 Other - Other
Our ENHANZE partners’ approved products...Read more

 Revenue - Product
We currently earn royalties from...Read more

 Revenue - Product
At the end of each...Read more

 Other - Other
As of December 31, 2023, we...Read more

 Revenue - Product
•In October 2023, BMS reported...Read more

 M & A - Other
We test for potential impairment...Read more

 Financial - Shares
We paid $250.0 million to...Read more

 Revenue - Product
The increase in royalties was...Read more

 Other - Other
The Breakthrough Therapy Designation for...Read more

 Other - Other
•In April 2023, Takeda announced...Read more

 Financial - Expense
Research and Development – Research...Read more

 Financial - Expense
The increase in research and...Read more

 Revenue - Product
For collaborative agreements, royalty revenue...Read more

 Revenue - Product
The decrease in revenue from...Read more

 Revenue - Product
We recognize revenue when it...Read more

 Financial - Shares
Share-Based PaymentsMethodologyJudgment and UncertaintiesEffect if...Read more

 Other - Other
•In February 2024, Takeda submitted...Read more

 Revenue - Product
The term loans are also...Read more

 Other - Other
ENHANZE may enable more flexible...Read more

 Other - Other
•In July 2023, Roche announced...Read more

 M & A - Other
Goodwill and IntangiblesMethodologyJudgment and UncertaintiesEffect...Read more

 Financial - Shares
Upon conversion, we will pay...Read more

 Financial - Shares
Upon conversion, we will pay...Read more

 Financial - Expense
Amortization of intangibles – The...Read more

 Other - Other
•In February 2024, argenx announced...Read more

 Other - Other
Actual results may differ from...Read more

 Financial - Income
The increase in income tax...Read more

 Other - Other
As of December 31, 2023, we...Read more

 Revenue - Product
The increase in net cash...Read more

 Financial - Expense
Cost of Sales – Cost...Read more

 Financial - Expense
Selling, General and Administrative –...Read more

 Financial - Expense
The increase in SG&A expenses...Read more

 Other - Other
•In January 2024, Janssen announced...Read more

 Financial - Expense
•the costs to develop and...Read more

 Revenue - Product
We expect product sales of...Read more

 Other - Other
We have contracted with third-party...Read more

 Other - Other
As of December 31, 2023, we...Read more

 Revenue - Product
In addition to receiving upfront...Read more

 Other - Other
We have lease arrangements related...Read more

 Financial - Shares
A 10% change in our...Read more

 Other - Other
Management’s Discussion and Analysis of...Read more

 Other - Other
This assessment is based on...Read more

 Other - Other
The expected timing of payments...Read more

 Mgmt Change - Other
•In September 2023, Chugai, a...Read more

 Financial - Expense
•the costs of filing, prosecuting,...Read more

 Other - Other
ENHANZE may enable fixed-dose SC...Read more

 Other - Other
•In November 2023, we and...Read more

 Revenue - Product
We expect royalty revenue to...Read more

 Other - Other
Acumen intends to explore the...Read more

 Other - Other
•In September 2023, Roche informed...Read more

 Other - Other
For obligations with cancellation provisions,...Read more

 Other - Other
Timing of payments and actual...Read more

 Financial - Expense
We do not currently believe...Read more

 Financial - Shares
If actual results are not...Read more

 Other - Other
We determine the grant date...Read more

 Other - Other
The conversion rate is subject...Read more

 Other - Other
Future interest payments associated with...Read more

 Other - Other
We license our technology to...Read more

 Other - Other
rHuPH20 works by breaking down...Read more

 Other - Other
We determine the fair value...Read more

 M & A - Other
We may, in the future,...Read more

 Other - Other
We determine the fair value...Read more

 Other - Other
We license the ENHANZE technology...Read more

 Revenue - Product
A revenue reversal will be...Read more

 Other - Other
•In November 2023, Teva announced...Read more

 M & A - Other
•the extent to which we...Read more

 Other - Other
The 2022 Facility will mature...Read more

 Revenue - Product
We expect these revenues to...Read more

 Other - Other
The inputs used in the...Read more

 Revenue - Product
Revenue RecognitionMethodologyJudgment and UncertaintiesEffect if...Read more

 Other - Other
•the terms and timing of...Read more

 Revenue - Product
Revenue from upfront licenses fees,...Read more

 Revenue - Product
If necessary, a true-up is...Read more

 Other - Other
The study met its primary...Read more

 Financial - Expense
Proceeds from a $120 million...Read more



 
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report





Audit Information





Cover





Consolidated Balance Sheets





Consolidated Balance Sheets (Parenthetical)





Consolidated Statements Of Cash Flows





Consolidated Statements Of Comprehensive Income





Consolidated Statements Of Income





Consolidated Statements Of Stockholders' Equity





Business Combination





Business Combination (Tables)





Business Combination - Intangible Assets Acquired (Details)





Business Combination - Narrative (Details)





Business Combination - Purchase Consideration (Details)





Business Combination - Schedule Of Assets Acquired And Liabilities Assumed (Details)





Business Combination - Summary Of Proforma Financial Information (Details)





Certain Balance Sheet Items





Certain Balance Sheet Items (Tables)





Certain Balance Sheet Items - Accounts Receivable, Net And Contract Assets (Details)





Certain Balance Sheet Items - Accrued Expenses (Details)





Certain Balance Sheet Items - Inventories (Details)





Certain Balance Sheet Items - Prepaid Expenses And Other Assets (Details)





Certain Balance Sheet Items - Property And Equipment (Details)





Certain Balance Sheet Items - Property And Equipment, Net Narrative (Details)





Commitments And Contingencies





Commitments And Contingencies (Tables)





Commitments And Contingencies - Annual Future Minimum Lease Payments (Details)





Commitments And Contingencies - Operating Leases Narative (Details)





Earnings Per Share





Earnings Per Share (Tables)





Earnings Per Share - Basic And Diluted Income Per Common Share Computation (Details)





Earnings Per Share - Shares Excluded From The Calculation Of Diluted Net Income Per Common Share (Details)





Employee Savings Plan





Employee Savings Plan (Details)





Fair Value Measurement





Fair Value Measurement (Tables)





Fair Value Measurement - Maturities (Details)





Fair Value Measurement - Narrative (Details)





Fair Value Measurement - Summary By Major Security Of Fair Value Measured On A Recurring Basis (Details)





Fair Value Measurement - Summary Of Available-For-Sale Securities (Details)





Goodwill And Intangible Assets





Goodwill And Intangible Assets (Tables)





Goodwill And Intangible Assets - Additional Information (Details)





Goodwill And Intangible Assets - Future Amortization (Details)





Goodwill And Intangible Assets - Goodwill Rollforward (Details)





Goodwill And Intangible Assets - Intangible Assets (Details)





Income Taxes





Income Taxes (Tables)





Income Taxes - Components Of Deferred Tax Assets (Liabilities) (Details)





Income Taxes - Income (Loss) Before Income Taxes Summarized By Region (Details)





Income Taxes - Income Tax Expense (Benefit) (Details)





Income Taxes - Narrative (Details)





Income Taxes - Schedule Of Income Tax Reconciliation (Details)





Income Taxes - Unrecognized Tax Benefit (Details)





Insider Trading Arrangements





Long-Term Debt, Net





Long-Term Debt, Net (Tables)





Long-Term Debt, Net - Carrying Value Of Debt, Components Of Interest Expense And Future Maturity (Details)





Long-Term Debt, Net - Components Of Interest Expense (Details)





Long-Term Debt, Net - Future Maturities And Interest Payments (Details)





Long-Term Debt, Net - Narrative (Details)





Organization And Business





Organization And Business (Details)





Pay Vs Performance Disclosure





Revenue





Revenue (Tables)





Revenue - Contract With Customer, Asset And Liability (Details)





Revenue - Disaggregation Of Revenue (Details)





Revenue - Narrative (Details)





Schedule Ii Valuation And Qualifying Accounts





Schedule Ii Valuation And Qualifying Accounts (Details)





Share-Based Compensation





Share-Based Compensation (Tables)





Share-Based Compensation - Narrative (Details)





Share-Based Compensation - Options (Details)





Share-Based Compensation - Performance Stock Units (Details)





Share-Based Compensation - Restricted Stock Units (Details)





Share-Based Compensation - Schedule Of Share-Based Compensation Expense (Details)





Share-Based Compensation - Unrecognized Expense (Details)





Share-Based Compensation - Valuation (Details)





Stockholders' Equity





Stockholders' Equity (Tables)





Stockholders' Equity - Narrative (Details)





Stockholders' Equity - Share Repurchase Activity (Details)





Summary Of Significant Accounting Policies





Summary Of Significant Accounting Policies (Policies)





Summary Of Significant Accounting Policies (Tables)





Summary Of Significant Accounting Policies - Accounts Receivable (Details)





Summary Of Significant Accounting Policies - Cash Flow Hedges, Currency Risk (Details)





Summary Of Significant Accounting Policies - Concentrations Of Credit Risk (Details)





Summary Of Significant Accounting Policies - Leases (Details)





Summary Of Significant Accounting Policies - Property And Equipment (Details)





Summary Of Significant Accounting Policies - Restricted Cash (Details)





Summary Of Significant Accounting Policies - Segment Information (Details)




 
Material Contracts, Statements, Certifications & more
Halozyme Therapeutics Inc provided additional information to their SEC Filing as exhibits





Exhibit 10.28: Material Contract





Exhibit 21.1: Subsidaries Of The Registrant





Exhibit 23.1: Consents Of Experts And Counsel





Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 32: Section 1350 Certification





Exhibit 97: Ex-97






Ticker: HALO CIK: 1159036
Form Type: 10-K Annual Report
Accession Number: 0001159036-24-000008
Submitted to the SEC: Tue Feb 20 2024 4:07:29 PM EST
Accepted by the SEC: Tue Feb 20 2024
Period:  Sunday, December 31, 2023
Industry: Biological Products No Disgnostic Substances						
External Resources:
 Stock Quote
 Social Media
 SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/halo/0001159036-24-000008.htm








About 
											Contact 
											Help 
											API 
											Privacy 
											Terms 
									


© 2012 - 2024 Last10K.com All Rights Reserved









×
You're Signed Out
Sign in for the full experience


Sign in
Join Now








Intrinsic Value Calculator








Screenshot of intrinsic value for AT&T (2019)




Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
Continue












Never Miss A New SEC Filing Again








Screenshot taken from Gmail for a new 10-K Annual Report




Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news
Continue












We Highlighted This SEC Filing For You








Screenshot taken from Wynn's 2018 10-K Annual Report




Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q
Continue












Widen Your SEC Filing Reading Experience








Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report




Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view
Continue












Uncover Actionable Information Inside SEC Filings








Screenshot taken from Lumber Liquidators 10-K Annual Report




Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Financial Stability Report








Screenshot of financial stability report for Coco-Cola (2019)




Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
Continue












Get a Better Picture of a Company's Performance








Available Financial Ratios




Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years
Continue












See when company executives buy or sell their own stock








Screenshot taken from Euronet (EEFT)




Last10K.com Member Feature

Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings
Continue












See how institutional managers trade a stock








Screenshot taken from General Motors (GM)




Last10K.com Member Feature

View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more
Continue












FREE Financial Statements








Screenshot of actual balance sheet from company 10-K Annual Report




Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREE












SEC Filing Exhibit
 PDF Download



Loading SEC Filing Exhibit...








SEC Filing Financial Summary
 PDF Download
 Excel Download



Loading SEC Filing Financial Summary...

